Groundbreaking Study on Risk Assessment of Breast Cancer Aims to Revolutionize Diagnosis and Treatment
CYduct Diagnostics (OTCPK:CYDX) announced the expansion of its patient study research on targeted breast cancer biomarkers for risk assessment and early detection. The groundbreaking study, supported by the Dr. Susan Love Fund for Breast Cancer Research at Tower Cancer Research Foundation, aims to identify specific biomarker combinations associated with breast cancer development.
Led by Dr. Jill Dietz and Dr. Shari Yosinski, the research utilizes next-generation automated ELISA technology to analyze noninvasively collected patient samples. The study's objective is to detect breast cancer indicators before they become apparent through traditional methods, potentially revolutionizing diagnosis approaches.
According to WHO data cited in the release, nearly 2.5 million women are diagnosed with breast cancer annually. The research aims to improve early detection capabilities, which could significantly enhance treatment outcomes and reduce the need for aggressive therapies.
CYduct Diagnostics (OTCPK:CYDX) ha annunciato l'espansione della sua ricerca sui biomarcatori mirati per il rischio e la rilevazione precoce del cancro al seno. Lo studio innovativo, supportato dal Dr. Susan Love Fund per la Ricerca sul Cancro al Seno presso la Tower Cancer Research Foundation, mira a identificare specifiche combinazioni di biomarcatori associate allo sviluppo del cancro al seno.
Guidata dalla Dr.ssa Jill Dietz e dalla Dr.ssa Shari Yosinski, la ricerca utilizza la tecnologia ELISA automatizzata di nuova generazione per analizzare campioni di pazienti raccolti in modo non invasivo. L'obiettivo dello studio è rilevare indicatori di cancro al seno prima che diventino evidenti attraverso metodi tradizionali, potenzialmente rivoluzionando gli approcci diagnostici.
Secondo i dati dell'OMS citati nel comunicato, quasi 2,5 milioni di donne vengono diagnosticate con cancro al seno ogni anno. La ricerca mira a migliorare le capacità di rilevazione precoce, il che potrebbe migliorare significativamente i risultati del trattamento e ridurre la necessità di terapie aggressive.
CYduct Diagnostics (OTCPK:CYDX) anunció la expansión de su investigación sobre biomarcadores específicos para la evaluación de riesgos y la detección temprana del cáncer de mama. El innovador estudio, apoyado por el Dr. Susan Love Fund para la Investigación del Cáncer de Mama en la Tower Cancer Research Foundation, tiene como objetivo identificar combinaciones específicas de biomarcadores asociadas con el desarrollo del cáncer de mama.
Dirigida por la Dra. Jill Dietz y la Dra. Shari Yosinski, la investigación utiliza la tecnología ELISA automatizada de nueva generación para analizar muestras de pacientes recolectadas de manera no invasiva. El objetivo del estudio es detectar indicadores de cáncer de mama antes de que se hagan evidentes a través de métodos tradicionales, lo que podría revolucionar los enfoques diagnósticos.
Según datos de la OMS citados en el comunicado, casi 2.5 millones de mujeres son diagnosticadas con cáncer de mama cada año. La investigación busca mejorar las capacidades de detección temprana, lo que podría mejorar significativamente los resultados del tratamiento y reducir la necesidad de terapias agresivas.
CYduct Diagnostics (OTCPK:CYDX)는 위험 평가 및 조기 발견을 위한 표적 유방암 바이오마커에 대한 환자 연구를 확장한다고 발표했습니다. 타워 암 연구 재단의 유방암 연구를 위한 수잔 러브 박사 기금의 지원을 받는 이 혁신적인 연구는 유방암 발생과 관련된 특정 바이오마커 조합을 식별하는 것을 목표로 합니다.
길 디츠 박사와 샤리 요신스키 박사가 이끄는 이 연구는 차세대 자동화 ELISA 기술를 사용하여 비침습적으로 수집된 환자 샘플을 분석합니다. 연구의 목표는 전통적인 방법으로 분명해지기 전에 유방암 지표를 발견하는 것으로, 이는 진단 접근 방식을 혁신적으로 변화시킬 수 있습니다.
발표된 자료에 따르면, 매년 거의 250만 명의 여성들이 유방암 진단을 받습니다. 이 연구는 조기 발견 능력을 개선하는 것을 목표로 하며, 이는 치료 결과를 크게 향상시키고 공격적인 치료의 필요성을 줄일 수 있습니다.
CYduct Diagnostics (OTCPK:CYDX) a annoncé l'expansion de sa recherche sur les biomarqueurs ciblés du cancer du sein pour l'évaluation des risques et la détection précoce. Cette étude révolutionnaire, soutenue par le Dr. Susan Love Fund pour la recherche sur le cancer du sein à la Tower Cancer Research Foundation, vise à identifier des combinaisons spécifiques de biomarqueurs associées au développement du cancer du sein.
Dirigée par le Dr. Jill Dietz et le Dr. Shari Yosinski, la recherche utilise la technologie ELISA automatisée de nouvelle génération pour analyser des échantillons de patients collectés de manière non invasive. L'objectif de l'étude est de détecter les indicateurs de cancer du sein avant qu'ils ne deviennent apparents par des méthodes traditionnelles, ce qui pourrait révolutionner les approches diagnostiques.
Selon les données de l'OMS citées dans le communiqué, près de 2,5 millions de femmes sont diagnostiquées avec un cancer du sein chaque année. La recherche vise à améliorer les capacités de détection précoce, ce qui pourrait considérablement améliorer les résultats des traitements et réduire le besoin de thérapies agressives.
CYduct Diagnostics (OTCPK:CYDX) hat die Erweiterung seiner Patientenstudie zu gezielten Biomarkern für das Risikoassessment und die frühzeitige Erkennung von Brustkrebs bekannt gegeben. Die bahnbrechende Studie, die vom Dr. Susan Love Fund für Brustkrebsforschung der Tower Cancer Research Foundation unterstützt wird, zielt darauf ab, spezifische Kombinationen von Biomarkern zu identifizieren, die mit der Entwicklung von Brustkrebs assoziiert sind.
Unter der Leitung von Dr. Jill Dietz und Dr. Shari Yosinski nutzt die Forschung automatisierte ELISA-Technologie der nächsten Generation, um nicht-invasiv gesammelte Patientenproben zu analysieren. Das Ziel der Studie ist es, Brustkrebsindikatoren zu erkennen, bevor sie durch traditionelle Methoden offensichtlich werden, was potenziell die Diagnoseansätze revolutionieren könnte.
Laut den im Bericht zitierten WHO-Daten werden jährlich fast 2,5 Millionen Frauen mit Brustkrebs diagnostiziert. Die Forschung zielt darauf ab, die Möglichkeiten zur frühzeitigen Erkennung zu verbessern, was die Behandlungsergebnisse erheblich verbessern und die Notwendigkeit aggressiver Therapien verringern könnte.
- Study has already obtained required patient samples
- Partnership with established Tower Cancer Research Foundation
- Development of noninvasive diagnostic technology
- Early-stage research with no immediate revenue impact
- No concrete timeline for study completion or results
- Faces competition from existing diagnostic methods
WESTPORT, CT / ACCESS Newswire / April 9, 2025 / CYduct Diagnostics, Inc. (OTCPK:CYDX) ("CYduct", or the "Company"), a precision medicine-based women's health company focused on the development of breast cancer risk assessment test and diagnostic tools, today announced it is expanding its patient study research on targeted breast cancer biomarkers for risk assessment leading to early detection.
A new study directed by CYduct Diagnostics, Inc. is set to transform the landscape of breast cancer risk assessment, focusing on the development of innovative early diagnostic techniques that could improve survival rates and treatment outcomes. This groundbreaking research, supported by the Dr. Susan Love Fund for Breast Cancer Research at Tower Cancer Research Foundation, seeks to identify specific biomarker combinations associated with breast cancer development allowing for the earliest detection possible, offering new hope to millions of women worldwide.
Breast cancer remains one of the most common and devastating cancers affecting women globally. According to the World Health Organization, nearly 2.5 million women are diagnosed annually, with early detection playing a critical role in overall survival prognosis. Despite advancements in screening methods such as mammography, many cases are still diagnosed at a later stage when the disease has spread, making treatment more difficult, and survival rates less than optimum.
The new study, led by Jill Dietz, M.D. and Shari Yosinski, Ph.D. aims to utilize innovative next-generation automated ELISA technology designed to deliver accurate, reproducible data, to assist in identifying breast cancer indications in noninvasively collected patient samples before it becomes detectable through traditional methods. The study has obtained the required patient samples and aims to offer crucial insights into risk assessment and better screenings that could save lives.
"We are excited about the possibilities this study holds for improving breast cancer risk assessment," said Dr. Jill Dietz, lead medical researcher and Chief Medical Officer. By identifying the disease at its earliest stages, we can significantly improve treatment outcomes, reduce the need for aggressive therapies, and ultimately save lives. This research could mark a transformative shift in the way we approach breast cancer diagnosis and contribute to incorporating a temporal aspect into breast cancer risk management. It allows women to determine if there are changes within their mammary ducts or if conditions remain stable."
About the Tower Cancer Research Foundation (TCRF):
TCRF was established in 1996 by a driven group of physicians, patients, and volunteers with a personal stake in cancer to fund high impact research and survivorship support programs. Today, TCRF continues to advance groundbreaking science and fund essential support for people affected by cancer. TCRF provides financial support to researchers, serving as a platform for further funding and discoveries internationally. Now, Tower Cancer Research Foundation extends its mission with the establishment of the Dr. Susan Love Fund for Breast Cancer Research. Dr. Susan Love established herself as a surgeon in Los Angeles, becoming a trailblazer and a beacon in the work to end breast cancer. The Dr. Susan Love Fund and TCRF's other programs are designed to maximize impact beyond the initial investment, benefiting researchers, patients and families today, with the potential to lead to even greater impact tomorrow. https://www.towercancer.org/
About CYduct Diagnostics, Inc.:
CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for screening, diagnosis, treatment and management of disease and medical conditions.
Additional information on its line of products will be available on the Company's website at: www.CYductDX.com.
FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION
This press release includes certain information that may constitute forward-looking statements. Forward-looking statements are typically identified by terminology such as "could," "may," "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "proposed," "planned," "potential" and similar expressions, or are those, which, by their nature, refer to future events. All statements, other than statements of historical fact, included herein, including statements about CYduct's beliefs and expectations, are forward-looking statements. Forward-looking information is necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Although CYduct believes that such statements are reasonable, it can give no assurance that such forward-looking information will prove to be accurate. CYduct cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors. Accordingly, due to the risks, uncertainties and assumptions inherent in forward-looking information, readers and prospective investors in the Company's securities should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof and is subject to change. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company assumes no obligation to revise or update forward-looking information to reflect new circumstances, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT:
CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYduct Diagnostics, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the main objective of CYDX's new breast cancer research study?
Who are the lead researchers in CYDX's breast cancer study?
What technology is CYDX using in their breast cancer research?
How many women are diagnosed with breast cancer annually according to CYDX's press release?
What organization is supporting CYDX's breast cancer research?
